Barclays Upgrades Edwards Lifesciences (NYSE:EW) to “Strong-Buy”

Edwards Lifesciences (NYSE:EW) was upgraded by Barclays to a “strong-buy” rating in a report released on Wednesday, Zacks reports.

Several other research analysts have also weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. BTIG Research reaffirmed a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences in a research note on Friday, September 11th. Piper Sandler reiterated an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $84.18 on Wednesday. The company’s fifty day moving average is $88.74 and its two-hundred day moving average is $86.17. The company has a market cap of $48.47 billion, a P/E ratio of 48.38, a price-to-earnings-growth ratio of 2.25 and a beta of 0.87. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,045 shares of company stock worth $451,596 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Institutional Trading of Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $1,274,082,000. Bank of America Corp DE bought a new position in Edwards Lifesciences during the second quarter worth $605,397,000. Deutsche Bank AG bought a new position in Edwards Lifesciences during the second quarter worth $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Edwards Lifesciences by 0.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after purchasing an additional 30,495 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Barclays initiated coverage with an Overweight rating, also reported as a Strong-Buy recommendation. The call provides fresh bullish support for Edwards’ structural-heart-device business and could help offset recent investor caution. Barclays initiates coverage of Edwards Lifesciences with overweight rating
• Neutral Sentiment: The next major catalyst is the third-quarter earnings report. Edwards plans to release results after the market closes on November 4, 2026, followed by a conference call. Investors may remain cautious while awaiting updated procedure volumes, revenue growth and guidance. Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
• Negative Sentiment: Insider selling is adding to the pressure. Vice President Daniel Lippis sold 619 shares worth approximately $53,000 under a pre-arranged Rule 10b5-1 trading plan. Broader data cited in the report show 24 insider sales and no purchases over the past six months, which may reinforce concerns about near-term sentiment, although planned sales are not necessarily a signal of deteriorating fundamentals. Edwards Lifesciences insider transaction filing
• Negative Sentiment: Investors may be taking profits ahead of the earnings and November 2 investor event. A recent analyst shift to Hold also weighed on sentiment. However, there was no clearly negative company update; Edwards recently announced FDA approval for its AUTUS pediatric pulmonary valve.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.